Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

The World Health Organization (WHO) declared that the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a pandemic [1]. Since the first confirmed case on January 22, 2020, the virus has been emerged in 216 countries. More than 14,765,000 laboratory-confirmed cases were reported, with an average mortality approaching 4.1% as of July 22, 2020 [2]. The spread of SARS-CoV-2 has led to serious socioeconomic consequences worldwide.

Currently, there is no specific treatment or vaccine for coronavirus disease 2019 (COVID-19). Up to 29% of the COVID-19 patients developed acute respiratory distress syndrome (ARDS) [3‐5] as a consequence of cytokine storm. ARDS was the major cause of morbidity [6]. Adjunctive corticosteroids may be theoretically beneficial [7], and has been widely used by clinicians to suppression of hyperinflammation in COVID-19 patients, especially those with critical illness [3, 5, 8]. However, there was comprehensive controversy on its efficacy [9, 10], due to the results of observational studies that showed corticosteroid treatment was associated with increased mortality and nosocomial infections for influenza and delayed virus clearance for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) [11].

In the early pandemic of COVID-19, lower mortality was reported among the critically ill subgroup of SARS patients treated with corticosteroids in a retrospective study [12]. Since then, evidence is growing that corticosteroid treatment is beneficial for some COVID-19 patients. The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial from the UK reported reduced mortality in patients treated with oral or intravenous dexamethasone 6 mg/d for up to 10 days [13]. The efficacy was significant only in severe patients who receiving oxygen or invasive mechanical ventilation. A prospective meta-analysis of 7 RCTs of critically ill patients with COVID-19 also showed the association between systemic corticosteroids and lower all-cause mortality [14]. Other two randomized controlled trials (RCTs) did not show benefit on mortality from intravenous dexamethasone or methylprednisolone treatment, but corticosteroid treatment increased ventilator-free days and number of days alive in patients with moderate to severe ARDS [15, 16]. A meta-analysis of corticosteroids on the mortality of ARDS showed beneficial effects of corticosteroids on short-term mortality may be counteracted by the delayed onset of adverse effects [17], such as secondary infection due to immunosuppression and altered tissue repair. A follow-up period of 28 days in these randomized trials may underestimate the late adverse effects of corticosteroids on all-cause mortality. In addition, most of the aforementioned trials studied dexamethasone, and evidence for methylprednisolone was limited.

In this observational study, we thoroughly examined the associations of corticosteroid treatment with 60-day in-hospital mortality among a population of COVID-19 patients who have developed ARDS.

A total of 1147 patients with COVID-19 were screened for the study. Forty patients were excluded for participating in any double-blind clinical trial (n = 15), death or discharge from the hospital within 2 days after hospital admission (n = 21), underwent long-term corticosteroid therapy for chronic kidney disease or rheumatic disease (n = 3), or no valid medical history provided because of mental disease (n = 1). From 1107 patients remained, 382 patients were identified as ARDS (Additional file 1: Fig. S1).

Baseline characteristics of the ARDS patients at hospital admission by receiving systemic corticosteroid treatment are shown in Table 1. In the entire cohort, the mean age was 60.7 ± 14.1 years, and 234 (61.3%) patients were male. 147 (38.5%) were treated with NIMV, 94 (24.6%) with IMV, and 11 (2.9%) with ECMO. All but one of the patients reached end point of decease (53.1%) or discharge (46.6%) during the follow-up period of 60 days. The median duration of follow-up was 12.0 (IQR 7.0–18.0) days. A total of 226 (59.2%) ARDS patients had a prescription of systemic corticosteroids. Corticosteroids were more likely prescribed to the younger (p = 0.0077) and males (p = 0.0135). Corticosteroids group had lower lymphocyte count and higher levels of CRP and lactate dehydrogenase at hospital admission than non-corticosteroids group, indicating a propensity in prescribing corticosteroids to patients with more severe immune dysfunction and inflammatory response (Table 1). The 60-day hospital death in patients who ever used corticosteroids was higher than the patients who did not use corticosteroids [135 (59.7%) vs. 68 (43.6%), p = 0.0019]. However, the median survival duration was longer in corticosteroid group [19.0 (IQR 15.0–21.0) vs. 15.0 (IQR 12.0–23.0), p = 0.0239].

Among patients prescribed corticosteroids, methylprednisolone was the most frequently administered corticosteroids (213/226, 94.2%) (Table 2). Corticosteroid treatment lasted for 7.0 (IQR 4.0–12.0) days in total. The maximum dose in methylprednisolone equivalent was 80.0 (IQR 40.0–80.0) mg per day and duration of maximum dose was 3.0 (IQR 2.0–5.0) days. Corticosteroids were initiated 13.0 (IQR 10.0–16.0) days after symptom onset. 82.3% (186/226) of the patients received corticosteroids started the therapy within 2 days after ARDS diagnosis. Survivors had shorter duration from symptom onset to corticosteroids [11.0 (9.0–14.0) vs. 14.00 (IQR 11.0–18.0), p = 0.0031] and had earlier initiation of corticosteroids with regard to the date of ARDS onset [0.0 (IQR − 1.0 to 1.0) vs. 1.00 (IQR 0.0–2.0), p = 0.0102] when compared with non-survivors. Clinical characteristics of survivors and non-survivors received corticosteroid are summarized in eTable 1 (Additional file 1).

In the logistic regression model generating propensity score, the pre-selected variables most closely correlated with prescription of systemic corticosteroids included age, blood lymphocyte count, heart rate and CRP (eTable 2, Additional file 1). The multivariable regression model of propensity for corticosteroid treatment had area under the receiver operating characteristic curve (ROC) of 0.71.

In survival analysis, univariable time-dependent Cox regression model showed the prescription of corticosteroids was associated with a lower risk of death (HR 0.48; 95% CI 0.25, 0.93; p = 0.0285) (Table 3). In full model adjusted for age, sex, SOFA score, propensity score, comorbidities, antiviral drugs, and respiratory supports, the association remained (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160) (Fig. 1).

In sensitivity analysis, narrowing to patients meet the Berlin definition of ARDS did not alter the association between corticosteroids and lower risk of death (HR 0.43; 95% CI 0.21, 0.88; p = 0.0208). The HR of corticosteroids on risk of death was constant when using hospital admission as baseline and excluding patients received corticosteroids 2 days after hospital admission (HR 0.37; 95% CI 0.18, 0.76; p = 0.0072). When using ARDS onset date as baseline, the associations between corticosteroids and the risk of death were also significant (Table 3).

Blood CRP level decreased among corticosteroids group on the first 4 days after ARDS onset (Fig. 2), while an increase was found in non-corticosteroids group. CRP levels were significantly lower in corticosteroids-treated group after 2 days of ARDS onset (p for interaction = 0.0434).

In this observational study, prescription of low-to-moderate dose systemic corticosteroids was associated with lower risk of 60-day in-hospital death among COVID-19 patients who developed ARDS. The efficiency of corticosteroids was further supported by the reduction of CRP, as the marker for suppressed systemic inflammation responses. No associations between corticosteroid treatment with viral shedding were found in our study.

Our study demonstrates the association between corticosteroid treatment with long-term (60 days) risk of death in severe COVID-19 patients. It is biologically plausible that suppression of inflammatory response by corticosteroids may be beneficial for patients with ARDS, which was caused by dysregulated systemic inflammation [3‐5] and proved the main cause of death. The RECOVERY trial and a metanalysis of ongoing RCTs showed reduced 28-day mortality and longer ventilation-free days in patients with corticosteroid treatment [13]. We used 60-day in-hospital death as primary endpoint. To our knowledge, it was longer than previously reported RCTs. The results showed significant association between corticosteroids and risk of death, which further provide evidence on the long-term benefit of corticosteroids. It was compatible with studies that indicated corticosteroid treatment was not associated with increases in secondary infections in COVID-19-related ARDS patients [15, 16].

Type, dosage, and duration of corticosteroids therapy were fundamental variables of corticosteroid treatment regimens. Different from the most of the published RCTs using dexamethasone, most of the patients in our study were treated with methylprednisolone. Methylprednisolone is a rapid onset glucocorticoid with shorter half-life and less mineralocorticoid effects than dexamethasone, which indicate shorter effects on systemic immunity and preventing corticosteroids-related fluid retention. Meduri et al. [22] firstly promoted the early use of corticosteroids in ARDS. They found that methylprednisolone reduced the duration of mechanical ventilation, ICU stay, and ICU mortality in early severe ARDS patients. In our study, a similar maximum dose (equivalent to methylprednisolone of 1–2 mg/kg) of corticosteroids was used, which was also close to the dose in RECOVERY trial and recommended by Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) for ARDS patients [23, 24]. Our results were in line with the RCTs of COVID-19 [13, 14] and previous studies of other ARDS patients, which showed low-dose corticosteroid treatment (equivalent to methylprednisolone of 1–2 mg/kg) accelerates the resolution of ARDS [23, 25, 26], indicating low-dose methylprednisolone as an alternative to dexamethasone in COVID-19-related ARDS. Higher dose may increase risks of immune-suppression and corticosteroid-induced complications [27‐29]. In this cohort, tapering strategy was performed as has been suggested by the guidelines for the ARDS-related corticosteroid insufficiency (CIRCI) to reduce deterioration from the development of a reconstituted inflammatory response and febrile response. Of note, a randomized trial included mild COVID-19 patients using a similar dose and shorter course of methylprednisolone (0.5 mg/kg twice daily for 5 days) than in the regimens of our study found no benefit on mortality. More research is needed to determine the best duration of corticosteroid therapy. A recent analysis of four trials showed prolonged corticosteroids therapy reduced mortality [25]. However, chronic side effects of corticosteroids including secondary infection and osteoporosis may occur in prolonged course of treatment.

Delayed virus clearance was reported in corticosteroid-treated patients with both SARS, MERS, and influenza [30‐32], which was a major concern for the immune suppressive effects of corticosteroids, albeit its uncertain clinical relevance. We found no difference in viral shedding duration from symptom onset between corticosteroid and non-corticosteroid groups, which may explain the heterogeneity in efficacy of corticosteroids between COVID-19 and other virus infections. Of note, positive SARS-CoV-2 test results have been reported after two consecutive negative results [33]. Viral tests of throat swabs were not monitored after two consecutive negative tests in our cohort. More evidence is needed for assessing the effects of corticosteroids on clearance of SARS-CoV-2 RNA.

We used rigorous statistical method to control for survival and indication bias. Survivors-treated bias exists in observational studies that assess exposure after the start of follow-up, where only patients survived long enough had an opportunity to receive the intervention. Therefore, the patients died early are more likely to be misclassified to the no-treatment group, leading to overestimation of the effectiveness of medicine [34]. This study was specifically designed to address survivors-treated bias of corticosteroid treatment, by using a time-dependent variable for corticosteroids initiation to define corticosteroids group and non-corticosteroids group [35]. In addition, there was a propensity of clinicians to give corticosteroids to patients who were critically ill in non-randomized clinical condition. The imbalance in baseline characteristics may introduce confounders in comparison of mortality between corticosteroids and non-corticosteroids group. In this cohort, lymphopenia and elevation of CRP and lactate dehydrogenase levels were more severe in patients who received corticosteroids therapy. Propensity score is a validated method to account for baseline confounding and control selection bias in this case [36]. In this study, we performed a rigorous propensity adjustment analysis accounting for the baseline variables related to propensity of corticosteroid treatment. These added to the strength of our results that found associations between corticosteroid treatment and risk of death.

Our study had some limitations. First, unlike randomized controlled trials, the selection bias and potential confounding effects might exist. We used propensity analysis rather than standard multivariable analysis to rigorously adjust for selection bias, and time-dependent model to avoid survivors-treated bias. Nonetheless, only measured factors were controlled for due to the nature of observational study design. Second, secondary infections were not monitored in this study, because microbiological culture results needed for definite diagnosis of secondary infection were possibly affected by antibiotic treatment the patients received simultaneously. To include the delayed effects of secondary infections on mortality, a longer follow-up period of 60 days was used. Third, this study was single center and patients were sicker and transferred from other hospital, so might lacking of generality. Forth, some of the patients were treated with Lopinavir–Ritonavir; it might be a confounder because the efficacy of Lopinavir–Ritonavir in COVID-19 was unclear. Fifth, our cohort was collected in the early outbreak of COVID-19; thus, the mortality was relatively higher than other studies, which limited generalization of our results.

Our findings suggest administration of low dose of corticosteroids might reduce the risk of death in COVID-19 patients who developed ARDS.